江苏省战略性新兴产业母基金(简称"江苏省战新母基金")第三批产业专项基金正式启动。 截至目前，江苏战新基金集群已经实现全省13个设区市全覆盖，重点投资新能源、新能源(智能网联)汽 车、低空经济和空天产业、新型电力(智能电网)、海工装备与高技术船舶、新材料等产业领域。 此外，江苏省农垦集团发起的规模10亿元的江苏农垦现代生物技术产业投资基金，将围绕医药健康、生 物农业、特色新型食品等相关领域开展直投，进一步加大省属企业战略性新兴产业投资布局，增强国有 企业核心功能、提高核心竞争力。 在扶持天使投资方面，由江苏高投集团和苏州创新投资集团共同发起的5亿元江苏省新智未来产业天使 投资基金，重在支持更多高层次人才创新创业，推动通用智能、先进计算、第三代半导体、量子科技、 合成生物、前沿新材料、深海、深地、空天开发等未来产业领域更多前沿科技成果转化落地，进一步服 务江苏省打造具有全球影响力的产业科技创新中心。 据悉，江苏省战新母基金自去年6月正式启动运作至今刚满一年，该基金充分发挥政府引导基金的撬动 效应，成效显著，有力支撑了全省战略性新兴产业和未来产业的发展壮大：目前两批产业专项基金共36 只、规模914亿元已全部组建 ...

7月11日，"产研融合加速 赋能肠道健康"中加益生元产研融合战略合作发布会上在北京举行，微生态健康食品开创品牌"轻又清"获得加拿大主板上市公司 BioNeutra（TSX.V:BGA）与惠买集团战略投资，估值数千万。 此次产研融合战略合作由"轻又清"发起，BioNeutra、惠买集团及青岛农业大学共同推动，助力中国益生元产业进入国际化产学研创新发展新阶段。北京协 和医院营养科主任马方、中科院微生物所研究员朱宝利、加拿大主板上市公司BioNeutra总裁朱建华、惠买集团董事长杜瑞勇、"轻又清"品牌创始人陈晓 强、青岛农业大学菊粉专项课题组代表秦洋、深创投北京公司总经理刘纲、和伙人平台董事长邱朝敏等重量级嘉宾出席此次发布会并致辞。 肠道健康问题已经成为不可忽视的隐患 随着社会经济的快速发展，老百姓的生活水平不断提高，大鱼大肉已成为餐桌上的家常便饭，而随之带来的高脂肪、膳食纤维长期摄入不足等营养不均衡问 题引发肠道健康问题，已经成为不可忽视的隐患。北京协和医院营养科主任马方表示，"菊粉是一种天然膳食纤维，也是一种优质益生元，是肠道益生菌的 营养素。经常补充益生元对肠道功能的恢复、肠道状态的稳定非常有帮助，我们在多年 ...

Core Viewpoint - The increasing use of AI health assistants among the elderly raises concerns about their ability to effectively filter misleading health information and provide reliable guidance, especially regarding "miracle drugs" and health rumors [2][3][13]. Group 1: AI Health Assistants Evaluation - A recent evaluation by Southern Metropolis Daily and Nandu Big Data Research Institute assessed 10 AI health assistants, including 5 general models and 5 specialized models, focusing on their ability to identify and correct health rumors [2][3]. - The tested AI health assistants generally performed well in recognizing health rumors and providing chronic disease management advice, but some failed to identify the exaggerated claims of "miracle drugs" [2][9]. - Specific models, such as Tongyi Qianwen and Quark Health Manager, incorrectly classified certain products as having scientific support for their efficacy, highlighting a reliance on promotional content rather than objective analysis [9][10]. Group 2: Misleading Health Claims - The evaluation identified several controversial products, such as "Can South Star Oral Liquid" and "Acid Friend Probiotic," which have been previously flagged for false advertising [3][4]. - Many AI models based their responses on promotional materials rather than authoritative sources, leading to potentially misleading conclusions about the efficacy of these products [10][12]. - The majority of AI health assistants were found to reference promotional content without consulting more credible sources or expert opinions, raising concerns about the reliability of their guidance [9][10]. Group 3: Rumor Correction and Chronic Disease Management - Despite shortcomings in identifying "miracle drugs," the AI health assistants demonstrated a high ability to recognize and correct common health rumors, using authoritative sources for analysis [13][14]. - The evaluation included specific inquiries about symptoms related to chronic diseases, where AI models provided structured guidance and recommendations based on the nature and risks of conditions like vascular plaque [14][15]. - Some specialized models offered additional services, such as connecting users to online consultations with doctors, enhancing the depth of their health management capabilities [14][15].

消费是拉动经济增长的"主引擎"，是畅通国内大循环的关键环节，也是人民对美好生活向往的直接体 现。新时代以来，我国发展面临的国际环境和国内条件发生深刻复杂变化，消费在推动经济发展中的地 位凸显。习近平总书记指出："要增强消费能力，改善消费条件，创新消费场景，使消费潜力充分释放 出来。"近年来，随着人民生活水平不断提高，健康消费逐渐成为我国新型消费市场的重要组成部分。 发展健康消费，既是顺应居民消费升级趋势、促进人的全面发展的内在要求，也是增强消费对经济发展 的基础性作用、促进社会再生产良性循环的重要举措。为此，要着力推动健康消费提质升级，在更好满 足人民美好生活需要的同时，不断增强消费对经济发展的基础性作用。 马克思主义认为，人的发展的最高境界是自由而全面的发展。人不仅需要具备基本的劳动能力，更要拥 有健康的体魄、健全的心理素质和良好的社会适应能力。健康是促进人的自由而全面发展的必然要求， 是广大人民群众的共同追求。健康消费是人们通过医疗保健、运动健身、生态居住等消费形式，对自身 生命质量进行维护与提升，包括健康食品、健康服务、健康产品、健康生活方式等方面的消费。 三是完善健康消费环境。深化特殊食品注册备案制度 ...

朋友们，最近南向资金的动作简直像开了加速器！一周净买入263亿港元，比上周多买了快90%，买卖总额更是超过6800亿港元，这热度堪比三伏天的北 京！更值得关注的是，有三只股票被南向资金直接买爆仓，持股量环比翻倍，连我这个20年的老司机都忍不住要跟大家好好唠唠。 先说这波资金为啥这么猛。明眼人都能看出来，政策端最近在疯狂释放利好。7月8号央行刚宣布把债券通南向通额度扩大到1万亿，允许券商、保险这些 机构下场，这相当于给港股开了个资金水龙头。再加上人民币国际化进程加速，聪明钱都在提前布局。就像我常说的，政策东风吹到哪儿，资金就会流 向哪儿，这次港股明显成了香饽饽。 第二个是中国春来。这名字听起来挺文艺，其实是民办高教领域的隐形冠军。旗下5所高校在校生超过10万人，而且特别会紧跟政策风向，把课程设置和 市场需求精准对接，毕业生就业率常年保持高位。最近教育部又在推数字化赋能教育，人家早就开始布局智慧校园了。更关键的是，公司连续三年分 红，今年还首次发了中期股息，这种现金流稳定、政策受益的标的，南向资金不抢才怪。 第三个必须聊聊宁德时代。这可是全球动力电池的龙头，最近港股更是玩出了新高度——溢价率直接飙到46%，创下双 ...

7月11日，第41批跨国公司地区总部和研发中心颁证暨外商投资集中签约仪式举行。仪式上，新认定的30家跨国公司地区总部与15家外资研发中心获颁 证书，56个外商投资项目完成签约，投资总额约36.8亿美元，其中33个项目现场签约。 上海市商务委介绍，此次获颁证书的跨国公司地区总部和外资研发中心，大多来自上海重点发展产业领域，涵盖生物医药、智能制造、时尚消费品等。 企业能级高，有7家世界500强企业，5家大中华区及以上区域总部和1家事业部总部。签约的外商投资项目主要集中在生物医药、时尚消费品、金融、汽车、 商务服务等重点领域，以及数字经济、绿色低碳等新赛道。 潘洁 摄 借总部东风，加速在华发展 隶属于新加坡电信集团（Singtel Group）的恩士迅（NCS）是亚太领先的数字与IT服务提供商。自1981年成立以来，凭借超40年IT项目交付经验，恩士 迅始终站在新加坡国家数字化进程前沿，为客户定制端到端信息化服务。 此次获颁跨国公司地区总部，恩士迅中国首席财务官陈星舸向《国际金融报》记者表示，在中国市场，恩士迅始终坚持致力于本士化发展战略，结合国 内市场的特色，与本地的生态系统进行深度合作。自1997年进入中国市场 ...

Core Viewpoint - After its IPO, the company "倍轻松" has experienced significant performance deterioration, raising concerns about the authenticity of its financials due to frequent changes in its CFO and substantial discrepancies in sales expenses before and after listing [1][3][5]. Group 1: Financial Performance - The company reported a drastic change in performance post-IPO, with continuous losses following a period of high revenue growth prior to listing [3][5]. - In 2022, 2023, and 2024, the company achieved revenues of 895 million, 1.275 billion, and 1.085 billion respectively, with net profits of -130 million, -55 million, and -3 million, marking three consecutive years of losses [5][6]. - The company's revenue peaked at 1.275 billion in 2023, but the first quarter of 2025 saw a 32.83% year-on-year decline in revenue [5]. Group 2: Sales Expenses and Employee Compensation - There is a notable discrepancy in sales expenses, with a significant increase in employee compensation post-IPO despite stable sales personnel numbers [19][21]. - The average salary for sales personnel rose from approximately 115,000 before the IPO to around 155,000 after, despite a decline in sales revenue [21][19]. - The company's sales expense ratio has increased dramatically, reaching as high as 54% post-IPO, compared to around 40% before [14][16]. Group 3: Marketing and Revenue Generation - The company has heavily invested in online marketing, with promotional expenses accounting for 64% of total sales expenses in 2023, raising questions about the sustainability of its business model [22][23]. - The online revenue constituted nearly 70% of total sales in 2023, but the high marketing costs have led to unprofitable operations [22][26]. - There are concerns about potential "fake orders" to inflate sales figures, as the company has reported significant promotional spending without corresponding profit [22][26]. Group 4: Corporate Governance and Control - The frequent turnover of the CFO raises red flags regarding corporate governance and financial oversight, with three CFOs in a short span [8][29]. - Allegations have emerged regarding the actual controller's potential misuse of company funds through suppliers, which could further undermine the integrity of financial reporting [29][30]. - The company has been scrutinized for its relationships with suppliers, where funds appear to be funneled to the actual controller, raising concerns about financial transparency [29][31].

证券代码：002044 证券简称：美年健康 公告编号：2025-040 美年大健康产业控股股份有限公司 关于实施 2024 年年度分红派息后发行股份购买资产暨关联交易 所涉发行股份购买资产的股份发行价格调整的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 因实施 2024 年年度分红派息，美年大健康产业控股股份有限公司（以下简 称"公司"）发行股份购买资产暨关联交易事项的股份发行价格将由 4.74 元/股调 整为 4.73 元/股。 本次交易中购买资产所涉及股份发行价格的定价基准日为公司第九届董事 会第七次（临时）会议决议公告之日，经交易各方友好协商，公司确定本次交易 的股份发行价格为 4.74 元/股，不低于定价基准日前 120 个交易日公司股票交易 均价的 80%。 在本次交易的定价基准日至发行日期间，上市公司如有派息、送股、资本 公积转增股本等除权、除息事项，发行价格将按下述公式进行调整，计算结果 向上进位并精确至分。发行价格的调整公式如下： 派发股票红利或资本公积转增股本：P1=P0/(1+n)； 配股：P1=(P0+A×k)/( ...

Meeting Overview - The 31st temporary meeting of the 8th Supervisory Board of Meinian Health Industry Holdings Co., Ltd. was held on July 11, 2025, via electronic means, with all three supervisors present [1][2]. Proposal for Asset Acquisition - The company plans to acquire equity stakes in 11 companies, including Hengyang Meinian Health Examination Center Co., Ltd., and minority stakes in 5 subsidiaries, including Zhengzhou Meijian Health Management Co., Ltd., through a share issuance [1][2][3]. Approval of Proposals - The Supervisory Board approved the proposal regarding the company's compliance with conditions for issuing shares to purchase assets, with a unanimous vote of 3 in favor [2][3]. - The proposal for the share issuance to purchase assets and related transactions was also approved, with a unanimous vote of 3 in favor [2][3]. Transaction Details - The transaction involves 37 counterparties, including individuals and companies, with specific equity stakes and transaction prices outlined for each [3][4]. - The transaction prices for key stakes include: - 84% of Hengyang Meinian for 33.6 million yuan - 81% of Ningde Meinian for 30.78 million yuan - 75% of Yantai Meinian for 35.8125 million yuan - 49% of Yantai Meinian Fudian for 12.25 million yuan - 90% of Feicheng Meinian for 22.5 million yuan [3][4]. Share Issuance Pricing - The share issuance price is set at 4.74 yuan per share, which is not less than 80% of the average trading price over the previous 120 trading days [5][6]. - The issuance price may be adjusted based on market conditions during the period from the pricing base date to the issuance date [6][7]. Lock-up Period and Profit Distribution - A lock-up period of 36 months is established for shares acquired by the counterparty, with conditions for extension based on stock performance [9][10]. - The profits generated during the transition period will belong to the company, while losses will be compensated by the counterparties based on their ownership percentages [10][11]. Compliance and Regulatory Approvals - The proposals will be submitted to the shareholders' meeting for approval, requiring a two-thirds majority of the voting rights present [2][11]. - The company has confirmed compliance with relevant laws and regulations regarding the asset acquisition and share issuance [12][13]. Future Shareholder Returns - The company has developed a three-year shareholder return plan for 2025-2027 to enhance shareholder value and ensure reasonable returns [26].

证券代码：002044 证券简称：美年健康 公告编号：2025-045 美年大健康产业控股股份有限公司 了《关于公司符合发行股份购买资产条件的议案》《关于公司发行股份购买资产 暨关联交易方案的议案》《关于＜美年大健康产业控股股份有限公司发行股份购 买资产暨关联交易报告书（草案）＞及其摘要的议案》等与本次交易相关的议案， 具体内容详见公司在指定媒体发布的相关公告。 本次交易尚需履行多项审批程序方可实施，包括但不限于公司股东大会批 准、深圳证券交易所审核通过、中国证券监督管理委员会同意注册等。本次交易 最终是否审批通过、相关程序履行完毕的时间存在不确定性。 公司将继续推进相关工作，严格按照相关法律法规的要求及时履行信息披露 义务，公司所有信息均以在指定信息披露媒体披露的内容为准。因本次交易的有 关事项尚存在不确定性，敬请广大投资者注意投资风险。 特此公告。 美年大健康产业控股股份有限公司 董 事 会 二〇二五年七月十二日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 美年大健康产业控股股份有限公司（以下简称"公司"）拟通过发行股份的方 式购买交易对方持有的衡阳美 ...